Overview: EDA Guidelines for Mock-Up Design of Human Pharmaceutical Products (2023)
The Egyptian Drug Authority (EDA) has issued the Guidelines for Mock-Up Design of Human Pharmaceutical Products to standardize how pharmaceutical packaging and labeling are designed and submitted for regulatory review in Egypt. These guidelines are essential for ensuring that packaging supports patient safety, clarity of information, and regulatory compliance.
- Objective and Scope
The primary aim of the guideline is to define how primary and secondary packaging (including labels and cartons) should be designed to meet EDA expectations. The guidance ensures that critical safety and product information is clearly legible and accessible, minimizing the risk of medication error. It applies to all human pharmaceutical products submitted to the EDA for registration or mock-up review. - Mock-Up Submission Requirements
All mock-ups must be submitted in full color.
A representative mock-up of the smallest marketed pack size for each strength and dosage form is required.
Labels for immediate packaging (e.g., blister, vial) and outer cartons must be provided.
Justification is required for any omission of information, especially in the case of imported products or small volume containers.
If languages other than Arabic and English are used, a certified translation may be requested. - Label Design Principles
The guidelines emphasize practical design principles that improve readability and user comprehension:
Legibility: Text must be easily readable, using appropriate fonts and size, and avoid excessive use of capital letters or italics.
Contrast and Layout: Color contrast should be optimized to highlight critical information such as product name, strength, dosage form, and warnings.
Consistency Across Products: Labels should be distinguished clearly between different strengths and products, and avoid similarity with other products that might cause confusion.
Minimized Use of Abbreviations: Abbreviations and ambiguous symbols should be minimized to prevent misinterpretation. - Mandatory Label Information
Principal Display Panel (PDP)
The most prominent part of the label should include:
Trade name
Active ingredient(s) and strength
Dosage form and route of administration
Net content and manufacturer information
MAH (Marketing Authorization Holder) details
EDA registration number and year
Manufacturing and expiry dates
Batch number
Approved price
All required data should appear in both Arabic and English where applicable. - Special Labeling Practices
Additional considerations include:
Blister Labels: Each unit should carry essential data such as product name, active ingredient, batch number, and expiry date.
Warnings and Instructions: Critical warnings must be visible on both primary and secondary packaging, using clear placement and color contrast.
Optional Features: QR codes are acceptable to help users access additional information, provided they align with EDA requirements.
Accessibility Considerations: Information in braille or designated dispensing label areas may be included to enhance accessibility. - Design Recommendations & Best Practices
The guideline also offers practical recommendations, such as:
Use consistent visual styles for primary and secondary packaging.
Avoid overcrowded information; allocate ample white space.
Consider placement of label elements to reduce potential confusion.
These recommendations align with global practices and refer to international label-design guidance used by other regulators such as the FDA and MHRA.
Conclusion
The EDA’s mock-up design guideline emphasizes clarity, safety, and regulatory consistency in pharmaceutical packaging. By standardizing the presentation of information and mandating essential design elements, the guideline aims to reduce medication errors and improve public health outcomes in the Egyptian market.
